Innovation in Drug Research and Development for Prevalent Chronic Diseases

Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug R&D for prevalent chronic diseases.Table of ContentsFront Matter1 Introduction2 Person-Centered Drug Research and Development3 New Technologies to Enable Research in Prevalent Chronic Disease4 Investment and Incentives5 Learning from Success6 Lessons Learned for the Future7 Reflections and Final ThoughtsAppendix A: Workshop AgendaAppendix B: Biographical Sketches of Workshop Speakers